Cancer patients requiring strong opioid analgesia (n= 202; mean age, 61.5 years; range, 18–
89 years; 55% men) were recruited from 38 United Kingdom palliative care centers into a …

PURPOSE To compare pain-related treatment satisfaction, patient-perceived side effects,
functioning, and well-being in patients with advanced cancer who were receiving either …

Purpose: To evaluate effectiveness and safety information of transdermal fentanyl
(TDF)(Duragesic/Durogesic*) and sustained-release oral morphine (SRM) in cancer pain …

Fentanyl is a synthetic opioid agonist which interacts primarily with the μ-opioid receptor.
The low molecular weight, high potency and lipid solubility of fentanyl make it suitable for …

PURPOSE: The aim of this study was to compare the analgesic and adverse effects, doses,
as well as cost of opioid drugs, supportive drug therapy and other analgesic drugs in …

Constipation and the use of laxatives were investigated in patients with chronic cancer pain
treated with oral morphine and transdermal fentanyl in an open sequential trial. Forty-six …

Objective: This randomised, multicentre, direct open comparative trial evaluated the efficacy,
treatment convenience, tolerability and safety aspects of transdermal therapeutic system …

Direct conversion from oral morphine to transdermal fentanyl with a ratio of oral
morphine/transdermal fentanyl (100: 1 mg) daily was examined in patients with cancer pain …

This study compares subcutaneous (sc) morphine and fentanyl with respect to pain control
and side effects using a 6-day randomized, double-blind, cross-over design. Results were …

Background: To assess the adverse effects of transdermal opiates treating moderate-severe
cancer pain in comparison with slow release oral morphine. Methods: A systematic review of …